Literature DB >> 8325885

Modulation of the human interleukin-6 promoter (IL-6) and transcription factor C/EBP beta (NF-IL6) activity by p53 species.

L Margulies1, P B Sehgal.   

Abstract

Constitutive up-regulation of interleukin-6 (IL-6) gene expression is observed in many neoplastic cell lines. The contribution of mutations in p53 to the up-regulation of the IL-6 promoter was evaluated in transient transfection experiments. In HeLa cells, wild-type (wt) human or murine p53 preferentially repressed the IL-6 promoter. The p53 mutants Val-135 and Phe-132 up-regulated IL-6 promoter activity in these cells at both 32.5 and 37 degrees C. The temperature-sensitive Val-135 mutant was not only not inhibitory or "wt-like" at the lower temperature, but had gained a transcriptional activator phenotype which was temperature-independent in HeLa cells. The functional DNA target for transcriptional modulation of the IL-6 promoter by p53 species included the multiple cytokine- and second messenger-response element (-173 to -145); point mutations in the transcription factor C/EBP beta-binding site within the second messenger-response element largely blocked the ability of p53 mutants Val-135 and Phe-132 to up-regulate this promoter. The up-regulation of IL-6 promoter constructs by co-transfection into HeLa cells of a C/EBP beta constitutive expression vector was blocked in a dominant negative manner by wt p53. In contrast, the p53 mutants Val-135 and Phe-132 further enhanced C/EBP beta-mediated up-regulation of IL-6 promoter constructs. The modulation of C/EBP beta function by p53 species provides a basis for the involvement of p53 not only in the regulation of cytokine synthesis but also in the altered responsiveness of tumor cells to cytokines.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8325885

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

1.  Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis.

Authors:  D Matas; A Sigal; P Stambolsky; M Milyavsky; L Weisz; D Schwartz; N Goldfinger; V Rotter
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

2.  Transcriptional repression by p53 involves molecular interactions distinct from those with the TATA box binding protein.

Authors:  G Farmer; P Friedlander; J Colgan; J L Manley; C Prives
Journal:  Nucleic Acids Res       Date:  1996-11-01       Impact factor: 16.971

3.  A novel lipopolysaccharide-induced transcription factor regulating tumor necrosis factor alpha gene expression: molecular cloning, sequencing, characterization, and chromosomal assignment.

Authors:  F Myokai; S Takashiba; R Lebo; S Amar
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

4.  p73 function is inhibited by tumor-derived p53 mutants in mammalian cells.

Authors:  C J Di Como; C Gaiddon; C Prives
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

5.  Transcriptional activation of the human epidermal growth factor receptor promoter by human p53.

Authors:  J H Ludes-Meyers; M A Subler; C V Shivakumar; R M Munoz; P Jiang; J E Bigger; D R Brown; S P Deb; S Deb
Journal:  Mol Cell Biol       Date:  1996-11       Impact factor: 4.272

6.  Identification and characterization of a nucleolar phosphoprotein, Nopp140, as a transcription factor.

Authors:  L H Miau; C J Chang; W H Tsai; S C Lee
Journal:  Mol Cell Biol       Date:  1997-01       Impact factor: 4.272

7.  C/EBPalpha is a DNA damage-inducible p53-regulated mediator of the G1 checkpoint in keratinocytes.

Authors:  Kyungsil Yoon; Robert C Smart
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

Review 8.  Emerging roles of p53 and other tumour-suppressor genes in immune regulation.

Authors:  César Muñoz-Fontela; Anna Mandinova; Stuart A Aaronson; Sam W Lee
Journal:  Nat Rev Immunol       Date:  2016-09-26       Impact factor: 53.106

9.  Interleukin-6 induces increased motility, cell-cell and cell-substrate dyshesion and epithelial-to-mesenchymal transformation in breast cancer cells.

Authors:  P B Sehgal
Journal:  Oncogene       Date:  2010-02-08       Impact factor: 9.867

10.  Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study.

Authors:  Ken H Young; Karen Leroy; Michael B Møller; Gisele W B Colleoni; Margarita Sánchez-Beato; Fábio R Kerbauy; Corinne Haioun; Jens C Eickhoff; Allen H Young; Philippe Gaulard; Miguel A Piris; Terry D Oberley; William M Rehrauer; Brad S Kahl; James S Malter; Elias Campo; Jan Delabie; Randy D Gascoyne; Andreas Rosenwald; Lisa Rimsza; James Huang; Rita M Braziel; Elaine S Jaffe; Wyndham H Wilson; Louis M Staudt; Julie M Vose; Wing C Chan; Dennis D Weisenburger; Timothy C Greiner
Journal:  Blood       Date:  2008-06-17       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.